Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes
- PMID: 11689887
- DOI: 10.1038/nm1101-1225
Protection of rhesus macaques against disease progression from pathogenic SHIV-89.6PD by vaccination with phage-displayed HIV-1 epitopes
Abstract
The antigenic polymorphism of HIV-1 is a major obstacle in developing an effective vaccine. Accordingly, we screened random peptide libraries (RPLs) displayed on phage with antibodies from HIV-infected individuals and identified an array of HIV-specific epitopes that behave as antigenic mimics of conformational epitopes of gp120 and gp41 proteins. We report that the selected epitopes are shared by a collection of HIV-1 isolates of clades A-F. The phage-borne epitopes are immunogenic in rhesus macaques, where they elicit envelope-specific antibody responses. Upon intravenous challenge with 60 MID50 of pathogenic SHIV-89.6PD, all monkeys became infected; however, in contrast to the naive and mock-immunized monkeys, four of five mimotope-immunized monkeys experienced lower levels of peak viremia, followed by viral set points of undetectable or transient levels of viremia and a mild decline of CD4+ T cells, and were protected from progression to AIDS-like illness. These results provide a new approach to the design of broadly protective HIV-1 vaccines.
Similar articles
-
Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.Vaccine. 2001 Dec 12;20(5-6):813-25. doi: 10.1016/s0264-410x(01)00408-x. Vaccine. 2001. PMID: 11738745
-
Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail.Virology. 2008 Jan 5;370(1):130-41. doi: 10.1016/j.virol.2007.08.022. Epub 2007 Oct 24. Virology. 2008. PMID: 17920095 Free PMC article.
-
Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.J Virol. 2005 Feb;79(3):1452-62. doi: 10.1128/JVI.79.3.1452-1462.2005. J Virol. 2005. PMID: 15650171 Free PMC article.
-
Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.Transfus Clin Biol. 2001 Aug;8(4):350-8. doi: 10.1016/s1246-7820(01)00187-2. Transfus Clin Biol. 2001. PMID: 11642027 Review.
-
Humoral immunity to HIV, SIV, and SHIV.AIDS. 1998;12 Suppl A:S121-32. AIDS. 1998. PMID: 9632993 Review. No abstract available.
Cited by
-
Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery.J Virol. 2008 Apr;82(8):4135-48. doi: 10.1128/JVI.00015-08. Epub 2008 Feb 13. J Virol. 2008. PMID: 18272584 Free PMC article.
-
Delivery strategies for novel vaccine formulations.World J Virol. 2012 Feb 12;1(1):4-10. doi: 10.5501/wjv.v1.i1.4. World J Virol. 2012. PMID: 24175206 Free PMC article.
-
HIV Vaccines: Biological and Clinical Considerations.Curr Infect Dis Rep. 2002 Aug;4(4):359-368. doi: 10.1007/s11908-002-0029-8. Curr Infect Dis Rep. 2002. PMID: 12126613
-
Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines.Viruses. 2014 Dec 17;6(12):5047-76. doi: 10.3390/v6125047. Viruses. 2014. PMID: 25525909 Free PMC article. Review.
-
Applying bioinformatics for antibody epitope prediction using affinity-selected mimotopes - relevance for vaccine design.Immunome Res. 2010 Nov 3;6 Suppl 2(Suppl 2):S6. doi: 10.1186/1745-7580-6-S2-S6. Immunome Res. 2010. PMID: 21067548 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials